Psychedelic Therapy & Law Update – April 2026

President Trump to Issue Executive Order on Ibogaine

President Trump will sign an executive order opening doors for more federal reserach on ibogaine, the naturally occuring psychedelic substance with indigenous roots in Africa. For more information, see this article by clicking here. Ibogaine has shown significant benefits for veterans suffering from war trauma, those suffering from opiate or drug addiction, and neurodegeneration conditions, among others. Several states have been moving forward with programs around ibogaine. Colorado is expected to add iboga/ibogaine to its state regulated in program in the coming years. Texas has a pilot program to research ibogaine for veterans. Ibogaine bills have been passed or are being considered in the following states: Arizona, California,  Indiana, Kentucky, Louisiana, Maryland, Massachusetts, Mississippi, Missouri,  New Hampshire, New York, Oklahoma, Oregon, Tennessee, Vermont, West Virginia,  and Ohio. The ibogaine retreat  market to address these mental health issues is largely outside of the United  States, primarily located in Mexico and, to a lesser extent, in Europe (e.g.,  Portugal) and the Caribbean. Over 10,000 people are estimated to have  taken ibogaine in countries where it is unregulated. The Executive Order will not reschedule ibogaine, which will remain a Schedule I substance. Contact Sean for more information or attend the ibogaine webinar discussed below.

Modern Psychedelics are a Mess (But Hope Remains)

As we celebrate Bicycle Day this month, (the day Albert Hoffman discovered LSD), I decided to write a little opinion piece on the state of psychedelics. Obviously there are some generalizations in this piece, but it expresses some of my hopes and concerns for the modern psychedelic movement. You can read the piece here.